These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 19446406

  • 1. Mast cell burden and reticulin fibrosis in the myeloproliferative neoplasms: a computer-assisted image analysis study.
    Ahmed A, Powers MP, Youker KA, Rice L, Ewton A, Dunphy CH, Chang CC.
    Pathol Res Pract; 2009; 205(9):634-8. PubMed ID: 19446406
    [Abstract] [Full Text] [Related]

  • 2. Plasma basic fibroblast growth factor and bone marrow fibrosis in clonal myeloproliferative disorders.
    Sayinalp N, Cinar H, Uner A, Haznedaroğlu IC, Büyükaşik Y, Göker H, Aksu S, Ozcebe OI, Karakuş S, Kirazli S, Dündar SV.
    Clin Lab Haematol; 2004 Aug; 26(4):265-8. PubMed ID: 15279663
    [Abstract] [Full Text] [Related]

  • 3. Association of mast cells and bone marrow reticulin fibrosis in patients with bcr-abl negative chronic myeloproliferative neoplasms.
    Keski H.
    Blood Cells Mol Dis; 2020 May; 82():102420. PubMed ID: 32179412
    [Abstract] [Full Text] [Related]

  • 4. Angiogenesis in chronic myeloproliferative diseases detected by CD34 expression.
    Panteli K, Zagorianakou N, Bai M, Katsaraki A, Agnantis NJ, Bourantas K.
    Eur J Haematol; 2004 Jun; 72(6):410-5. PubMed ID: 15128419
    [Abstract] [Full Text] [Related]

  • 5. The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms.
    Tadmor T, Bejar J, Attias D, Mischenko E, Sabo E, Neufeld G, Vadasz Z.
    Am J Hematol; 2013 May; 88(5):355-8. PubMed ID: 23494965
    [Abstract] [Full Text] [Related]

  • 6. Fibrosis in Hodgkin and non-Hodgkin lymphomas.
    Tataroglu C, Sarioglu S, Kargi A, Ozkal S, Aydin O.
    Pathol Res Pract; 2007 May; 203(10):725-30. PubMed ID: 17804176
    [Abstract] [Full Text] [Related]

  • 7. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.
    Tefferi A, Thiele J, Vardiman JW.
    Cancer; 2009 Sep 01; 115(17):3842-7. PubMed ID: 19472396
    [Abstract] [Full Text] [Related]

  • 8. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
    Orazi A.
    Pathobiology; 2007 Sep 01; 74(2):97-114. PubMed ID: 17587881
    [Abstract] [Full Text] [Related]

  • 9. Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases.
    Santana-Davila R, Tefferi A, Holtan SG, Ketterling RP, Dewald GW, Knudson RA, Steensma DP, Chen D, Hoyer JD, Hanson CA.
    Leuk Res; 2008 Dec 01; 32(12):1927-30. PubMed ID: 18538839
    [Abstract] [Full Text] [Related]

  • 10. The role of beta-catenin in chronic myeloproliferative disorders.
    Jauregui MP, Sanchez SR, Ewton AA, Rice L, Perkins SL, Dunphy CH, Chang CC.
    Hum Pathol; 2008 Oct 01; 39(10):1454-8. PubMed ID: 18619646
    [Abstract] [Full Text] [Related]

  • 11. Study of significance of bone marrow microvessel density in myeloproliferative neoplasms in correlation with CD34 blasts, mast cell count and fibrosis.
    Thomas K, Rao R, G V C, Rai S, Rao A R S, Basavaraju Vatsala K.
    F1000Res; 2023 Oct 01; 12():503. PubMed ID: 38434629
    [Abstract] [Full Text] [Related]

  • 12. [Histopathology and molecular pathology of chronic myeloproliferative disorders].
    Kreipe HH.
    Veroff Pathol; 1993 Oct 01; 141():1-158. PubMed ID: 8372486
    [Abstract] [Full Text] [Related]

  • 13. Increased Dkk3 protein expression in platelets and megakaryocytes of patients with myeloproliferative neoplasms.
    Medinger M, Tzankov A, Kern J, Pircher A, Hermann M, Ott HW, Gastl G, Untergasser G, Gunsilius E.
    Thromb Haemost; 2011 Jan 01; 105(1):72-80. PubMed ID: 20978717
    [Abstract] [Full Text] [Related]

  • 14. Chronic myeloproliferative diseases on a pathologist's desk--a dilemma of distinct entities versus a clinico-pathologic continuum. A descriptive study based on a material from the Polish population.
    Rudzki Z, Papla B, Stachura J.
    Pol J Pathol; 2004 Jan 01; 55(1):13-23. PubMed ID: 15195702
    [Abstract] [Full Text] [Related]

  • 15. Bone marrow mast cell morphologic features and hematopoietic dyspoiesis in systemic mast cell disease.
    Stevens EC, Rosenthal NS.
    Am J Clin Pathol; 2001 Aug 01; 116(2):177-82. PubMed ID: 11488063
    [Abstract] [Full Text] [Related]

  • 16. Molecular pathology of myeloproliferative neoplasms.
    Klco JM, Vij R, Kreisel FH, Hassan A, Frater JL.
    Am J Clin Pathol; 2010 Apr 01; 133(4):602-15. PubMed ID: 20231614
    [Abstract] [Full Text] [Related]

  • 17. [The value of the initial bone biopsy in chronic myeloproliferative syndromes. Review of 80 cases].
    Ortuño F, Zuazu I, Bordes R, Brunet S, Puig J, Ayats R.
    Sangre (Barc); 1989 Apr 01; 34(2):117-25. PubMed ID: 2667169
    [Abstract] [Full Text] [Related]

  • 18. Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis.
    Hahn HP, Hornick JL.
    Am J Surg Pathol; 2007 Nov 01; 31(11):1669-76. PubMed ID: 18059223
    [Abstract] [Full Text] [Related]

  • 19. Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies.
    Ellis JT, Peterson P, Geller SA, Rappaport H.
    Semin Hematol; 1986 Apr 01; 23(2):144-55. PubMed ID: 3704666
    [Abstract] [Full Text] [Related]

  • 20. The bone marrow in urticaria pigmentosa and systemic mastocytosis. Cell composition and mast cell density in relation to urinary excretion of tele-methylimidazoleacetic acid.
    Ridell B, Olafsson JH, Roupe G, Swolin B, Granerus G, Rödjer S, Enerbäck L.
    Arch Dermatol; 1986 Apr 01; 122(4):422-7. PubMed ID: 3954410
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.